How has been the historical performance of Pharmaids Pharma?

Answer:The historical performance of Pharmaids Pharma shows a gradual increase in net sales, reaching 19.45 Cr in March 2025, up from 15.11 Cr in March 2024 and starting from 0.00 Cr in March 2023. However, the company has consistently reported negative operating profits, with an operating profit of -12.66 Cr in March 2025, slightly worse than -12.33 Cr in March 2024 and -9.88 Cr in March 2023. The total expenditure has risen to 32.21 Cr in March 2025 from 28.32 Cr in March 2024, contributing to a profit before tax of -17.28 Cr in March 2025, compared to -15.62 Cr in March 2024 and -9.91 Cr in March 2023. The profit after tax also reflects this trend, with losses of -13.51 Cr in March 2025, -11.84 Cr in March 2024, and -7.56 Cr in March 2023. The company's total assets increased to 109.35 Cr in March 2025 from 84.67 Cr in March 2024, while total liabilities also rose to 109.35 Cr from 84.67 Cr, indicating a growing financial burden. Cash flow from operating activities remained negative at -13.00 Cr in March 2025, worsening from -10.00 Cr in March 2024.

Breakdown:
Pharmaids Pharma has demonstrated a notable increase in net sales over the past three years, achieving 19.45 Cr in March 2025, which marks a significant rise from 15.11 Cr in March 2024 and an initial 0.00 Cr in March 2023. Despite this growth in revenue, the company has faced persistent challenges with profitability, as evidenced by its operating profit margins remaining deeply negative, culminating in an operating profit of -12.66 Cr in March 2025. The total expenditure has also escalated, leading to a profit before tax of -17.28 Cr in March 2025, reflecting a deterioration in financial performance compared to previous years. The company's total assets and liabilities have both increased, reaching 109.35 Cr in March 2025, indicating a rise in financial obligations. Furthermore, the cash flow from operating activities has remained negative, highlighting ongoing operational difficulties. Overall, while Pharmaids Pharma has shown growth in sales, it continues to struggle with significant losses and rising costs.